Kim, Seong A. Kim, Seohyun Hong, Yeonsun Choi, Yoonjeong Lee, Yeji Kwon, Minsu Park, Seung-Yoon Jeong, Cherlhyun Nam, Gi-Hoon Han, Rafael T. Kim, In-San 2025-01-07T05:30:18Z 2025-01-07T05:30:18Z 2024-12-30 2025-01 1936-5233 https://pubs.kist.re.kr/handle/201004/151485 Immune checkpoint inhibition shows promise for cancer treatment, but only a minority of patients respond. Combination strategies have been explored to overcome this resistance. Combining immunogenic clearance using immunogenic cell death inducers with a rho kinase inhibitor enhances phagocytosis of immunogenically dying cancer cells by antigen-presenting cells, stimulating tumor-specific immune responses by activating CD8 & thorn; T cells via dendritic cell-mediated priming. This approach increases the responsiveness of immune checkpoint blockade (ICB)-resistant cancer to ICB. However, the precise mechanisms remain unclear. This study elucidates cellular mechanisms of immunogenic clearance enhancing ICB response. Using single-cell RNA sequencing, we observed an increase in effector memory-like CD8 & thorn; T cells within the tumor microenvironment with combined treatment. We propose this cell cluster may originate from proliferating CD8 & thorn; T cells elevated by immunogenic clearance. Notably, abundant effector memory-like CD8 & thorn; T cells in ICB-responsive patients suggest their antitumor effect. Thus, increasing this cell population through enhanced T cell priming may improve the response of ICB-resistant tumors. English Neoplasia Press Immunogenic clearance combined with PD-1 blockade elicits antitumor effect by promoting the recruitment and expansion of the effector memory-like CD8+ T cell Article 10.1016/j.tranon.2024.102209 1 Translational Oncology, v.51 Translational Oncology 51 Y scie scopus 001373063900001 2-s2.0-85210116049 Oncology Oncology Article CD8(+) T-CELLS I IFN THERAPY DIFFERENTIATION IMMUNOTHERAPY MECHANISMS IMMUNE Immunotherapy Immune checkpoint inhibitor Combination therapy Single cell RNA sequencing CD8+T cell